Provider of independent advisory and product development services focused on science and technology initiatives
28-Feb-2018 – 216.9p – £85.4m – PER 15.2
Audited Results For The 12 Months To End December 2017 – Seems in-line, not exactly inspiring.
A new one for me. Looks OK but seems (perhaps) fairly priced round about here – Although the company is seeking the right to buy back up to 10% of the shares. Will keep an eye out on future updates.
19-Apr-2018 – 204p – £81.6m – PER 13.6
Business Update – 2018 Q1 Revenue and Profits ahead of the Board’s expectations. Buy Back program, up to £100,000 per calendar month capped at £1m annually.
Quite like this but just not yet tempted enough, will keep an eye out for updates.
24-Jul-2018 – 240p – £96.0m – PER 15.8
Interim Results For The 6 Months To End June 2018 – In-line with Revenue up over 30%, PBT up 10% and EPS up 15%.
Still quite like this but just not enough – I remain Neutral for now.
14-Dec-2018 – 215p – £86.1m – PER 14.6
Trading Update And Termination Of Formal Sale Process – Trading in the 11 months to end November in-lin2 with the Board’s expectations. Sale process ended, Brexit and even the world to blame! Buy-back programme will be re-introduced.
There still seems a reasonable amount to like here, except for the fact it’s not an attractive acquisition for anybody – And the whole world is to blame!